Adenovirus News and Research

RSS

Adenoviruses most commonly cause respiratory illness; however, depending on the infecting serotype, they may also cause various other illnesses, such as gastroenteritis, conjunctivitis, cystitis, and rash illness. Symptoms of respiratory illness caused by adenovirus infection range from the common cold syndrome to pneumonia, croup, and bronchitis. Patients with compromised immune systems are especially susceptible to severe complications of adenovirus infection. Acute respiratory disease (ARD), first recognized among military recruits during World War II, can be caused by adenovirus infections during conditions of crowding and stress.

Start codon disruption with CRISPR-Cas9 gene editing prevents Fuchs’ corneal dystrophy in mice

In a new study, researchers at the University of Oregon's Phil and Penny Knight Campus for Accelerating Scientific Impact used start codon disruption with CRISPR-Cas9 gene editing to prevent Fuchs' corneal dystrophy in mice.

3 Aug 2021

Cancer vaccine reduces tumor burden, improves survival in animal model of Lynch syndrome

A new strategy for developing vaccines against cancer showed promise in a proof-of-concept study led by scientists at Weill Cornell Medicine, NewYork-Presbyterian and Heidelberg University Hospital.

2 Aug 2021

Risk of venous thrombosis is higher in SARS-CoV-2 infection than vaccination

A study has revealed that adenovirus vector and mRNA-COVID-19 vaccines are associated with an increased risk of thromboembolism and thrombocytopenia.

1 Aug 2021

Prior SARS-CoV-2 infection enhances Johnson and Johnson Ad26.COV2.S vaccine immunogenicity

A new study reports that the Johnson and Johnson vaccine against COVID-19 shows enhanced efficacy when administered to individuals with pre-existing antibodies.

30 Jul 2021

SARS-CoV-2 spike-specific antibodies induced in breast milk by COVID-19 vaccines

An interesting new paper examines how these vaccines can help young patient populations to withstand the virus.

27 Jul 2021

Study shows inhalable nanocatchers can protect lung cells against SARS-CoV-2

Inhalable nanocatchers that contain hACE2 have been recently developed by a group of researchers, providing a plethora of potential benefits in comparison to existing treatments against COVID-19.

27 Jul 2021

How SARS-CoV-2 vaccination symptoms differ from early COVID-19 symptoms

A new study published on the preprint server medRxiv* presents an analysis of the differences between recorded vaccination side effects vs. early COVID-19 symptoms. The researchers focused on four vaccines, namely, Pfizer-BioNTech (PB) mRNA (BNT162b2) vaccine, based on messenger ribonucleic acid encoding the viral spike protein; the Moderna mRNA (mRNA-1273) vaccine; the Oxford-AstraZeneca (O-AZ) adenovirus-vectored vaccine; and the Janssen adenovirus-vectored Ad26.COV2.S).

26 Jul 2021

Study compares mRNA and adenovirus-based SARS-CoV-2 vaccines against variants of concern

In a research paper recently uploaded to the preprint server bioRxiv by Tada et al. (July 19th, 2021) the neutralizing capacity of antibodies generated by either messenger RNA (mRNA) or adenoviral vector-based vaccines against Beta, Delta, Delta plus, and Lambda variants are investigated, among others, highlighting the importance of continued SARS-CoV-2 genomic surveillance.

26 Jul 2021

Advantages and challenges of intranasal vaccines to fight against COVID-19 infections

There are many reasons that an intranasal vaccine against the SARS-CoV-2 virus would be helpful in the fight against COVID-19 infections, University of Alabama at Birmingham immunologists Fran Lund, Ph.D., and Troy Randall, Ph.D., write in a viewpoint article in the journal Science.

23 Jul 2021

Study suggests COVID-19 vaccine confidence and hesitancy in the UK driven by trust, not misinformation

An interesting new study reports that vaccine hesitancy in the UK is driven not, as is commonly thought, by the so-called ‘infodemic’ of misinformation that has characterized much public messaging during the COVID-19 pandemic. Instead, the personality of the individual, the ability to trust scientific and government leadership, political affiliations, and openness relative to the process of vaccine development was found to be key in the development of this attitude.

20 Jul 2021

Evaluation of a synthetic DNA SARS-CoV-2 vaccine INO-4800 using a nonhuman primate model

A new study published in Vaccine assesses the safety and efficacy of the synthetic DNA vaccine candidate INO-4800, delivered as a single or double dose regime.

18 Jul 2021

Gene therapy delivered into the brain may be safe, effective in treating rare neurological disorder

A new study published in Nature Communications suggests that gene therapy delivered into the brain may be safe and effective in treating aromatic L-amino acid decarboxylase (AADC) deficiency.

16 Jul 2021

Initial SARS-CoV-2 vaccination response may predict BNT162b2 booster response, but not AZD1222

A new study finds that the antibody titer values prior to the booster dose of the BNT162b2 vaccine can predict the final antibody response after two doses.

11 Jul 2021

Durable antibody response at least 8 months following vaccination with J&J COVID vaccine

A recent study by a team of scientists at Beth Israel Deaconess Medical Center and Janssen Vaccines & Prevention has demonstrated that humoral and cellular immunity elicited by the coronavirus disease 2019 (COVID-19) vaccine Ad26.COV2.S remains active for at least eight months.

9 Jul 2021

Researchers discover how vaccine-induced immune thrombotic thrombocytopenia happens

A McMaster University team of researchers recently discovered how, exactly, the COVID-19 vaccines that use adenovirus vectors trigger a rare but sometimes fatal blood clotting reaction called vaccine-induced immune thrombotic thrombocytopenia or VITT.

7 Jul 2021

Intranasal COVID-19 vaccine developed from bacterial extracellular vesicle induces robust antibody response in preclinical trials

A team of US-based scientists recently developed a novel vaccine candidate against SARS-CoV-2, the causative pathogen of COVID-19. The vaccine is composed of extracellular vesicles of Salmonella typhimurium incorporated with the spike receptor-binding domain (RBD) of SARS-CoV-2. Upon intranasal administration in hamsters, the vaccine induces strong blood antibody titers and protects against severe COVID-19.

30 Jun 2021

Is the SARS-CoV-2 delta variant threatening vaccine efficacy?

A new study in the UK, by researchers at Imperial College London, The Francis Crick Institute and the University of Glasgow, explores the loss of coronavirus disease 2019 (COVID-19) vaccine efficacy against the virus behind the current pandemic caused by the emergence of newer variants that have undergone mutational escape.

30 Jun 2021

More evidence that mixing COVID-19 vaccines may help elicit a robust immune response

Eight volunteers who received a complete dose or a single dose of an mRNA vaccine or the ChAdOx1 vaccine after a dose of a trial gorilla adenovirus vaccine showed a significantly high level of antibodies and T cell response against SARS-CoV-2.

29 Jun 2021

Nanotechnology and the fight against COVID-19

In a review paper published in the open-access MDPI journal Viruses, a team of researchers explored the potential of nanotechnology to alleviate the current and future coronavirus burden. The team focused on its potential role in the detection, diagnosis, protection, and treatment of SARS-CoV-2 infection.